Use of TNFα inhibitor for treatment of psoriatic arthritis

US9085620B1 · kind B1 · utility

Assignee

• AbbVie Biotechnology Ltd. · BM

Inventors

• Rebecca S. Hoffman · Wilmette, US
• Mark Weinberg · Northbrook, US
• Subhashis Banerjee · Hamden, US
• Lori K. Taylor · Boston, US
• Clive E. Spiegler · Skillman, US
• Daniel Edward Tracey · Harvard, US
• Elliot K. Chartash · Dover, US
• William T. Barchuk · San Diego, US
• Philip Yan · Vernon Hills, US
• Anwar Murtaza · North Grafton, US
• Jochen G. Salfeld · North Grafton, US
• Steven A. Fischkoff · Short Hills, US
• George R. Granneman · Lindenhurst, US

Key dates

• Filing date: Apr 8, 2015
• Grant date: Jul 21, 2015
• Expiry date: Apr 8, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.